NASDAQ · SCTL
Healthcare · Drug Manufacturers - Specialty & Generic
$1.10
Up+$0.01 (+0.92%)
Updated Aug 14, 2026, 3:07 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SCTL does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SCTL.
SCTL research
Company profile and research snapshot.
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 29, 2024 | RBC Capital | Sector Perform | — |
| Nov 9, 2023 | RBC Capital | Outperform | — |
| Aug 15, 2023 | RBC Capital | Outperform | — |
| Aug 15, 2023 | Stephens & Co. | Overweight | — |
| Jun 12, 2023 | RBC Capital | Outperform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Apr 8, 2024
CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. (“CoreRx”) today announced that it has completed its acquisition of Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily focused on small molecule therapeutics.
Benzinga · Feb 29, 2024
Privately held CoreRx Inc. will acquire Societal CDMO Inc (NASDAQ:SCTL), a contract development and manufacturing organization. CoreRx on Wednesday said it will commence a tender offer to acquire all outstanding shares of Societal CDMO for $1.10 per share in cash. “We are pleased to enter into this transaction with CoreRx, which delivers substantial value to our shareholders and is the outcome of a thorough review process overseen ...Full story available on Benzinga.com
GlobeNewswire Inc. · Feb 28, 2024
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging
GlobeNewswire Inc. · Feb 1, 2024
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SCTL.
No results
No recent SID articles mention SCTL.
